Free Trial

Editas Medicine (EDIT) News Today

→ Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad)
Free EDIT Stock Alerts
$5.32
+0.02 (+0.38%)
(As of 04:14 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends
June 10 at 1:52 AM | marketbeat.com
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recommendation of "Hold" from Analysts
Shares of Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) have received an average recommendation of "Hold" from the eleven research firms that are covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a hold recommendation and five have given a buy r
June 9 at 11:16 AM | marketbeat.com
Seven Eight Capital LP Acquires New Holdings in Editas Medicine, Inc. (NASDAQ:EDIT)
Seven Eight Capital LP purchased a new position in shares of Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 146,345 shares of the company's stock, valued at approxima
June 9 at 5:56 AM | americanbankingnews.com
Insider Selling: Editas Medicine, Inc. (NASDAQ:EDIT) CEO Sells $67,050.50 in Stock
June 8 at 5:50 AM | marketbeat.com
Rafferty Asset Management LLC Sells 152,799 Shares of Editas Medicine, Inc. (NASDAQ:EDIT)
Rafferty Asset Management LLC lowered its position in shares of Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) by 27.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 409,065 shares of the company's stock after selli
June 7 at 8:40 AM | insidertrades.com
Gilmore Neil O'neill Sells 12,191 Shares of Editas Medicine, Inc. (NASDAQ:EDIT) Stock
June 6, 2024 | marketbeat.com
Insider Selling: Editas Medicine, Inc. (NASDAQ:EDIT) CEO Sells 12,191 Shares of Stock
Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) CEO Gilmore Neil O'neill sold 12,191 shares of the business's stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $5.50, for a total transaction of $67,050.50. Following the completion of the sale, the chief executive officer now directly owns 315,279 shares of the company's stock, valued at $1,734,034.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
June 4, 2024 | marketbeat.com
Dimensional Fund Advisors LP Raises Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT)
Dimensional Fund Advisors LP boosted its stake in shares of Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) by 40.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 2,392,396 shares of the company's stock after buying an additional 690,366 shares durin
June 1, 2024 | americanbankingnews.com
Equities Analysts Set Expectations for Editas Medicine, Inc.'s FY2024 Earnings (NASDAQ:EDIT)
May 31, 2024 | marketbeat.com
Brokers Issue Forecasts for Editas Medicine, Inc.'s FY2024 Earnings (NASDAQ:EDIT)
Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Equities research analysts at Chardan Capital reduced their FY2024 earnings estimates for shares of Editas Medicine in a research report issued on Tuesday, May 28th. Chardan Capital analyst Y. Livshits now forecasts that the company will earn ($
May 31, 2024 | americanbankingnews.com
Editas Medicine (NASDAQ:EDIT) Price Target Cut to $7.00 by Analysts at Evercore ISI
May 30, 2024 | marketbeat.com
Evercore ISI Trims Editas Medicine (NASDAQ:EDIT) Target Price to $7.00
Evercore ISI reduced their price target on Editas Medicine from $15.00 to $7.00 and set an "in-line" rating on the stock in a report on Thursday.
May 28, 2024 | finance.yahoo.com
Azzur Cleanrooms on Demand™ Grand Opening in Devens, MA Brings Together Local, State and Life Sciences Leaders
May 25, 2024 | marketbeat.com
Editas Medicine, Inc. (NASDAQ:EDIT) Shares Sold by BNP Paribas Financial Markets
BNP Paribas Financial Markets cut its position in Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) by 60.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 215,011 shares of the company's stock after selling
May 23, 2024 | msn.com
Unique gene editing drug could treat genetic blindness, but how it compares to existing therapies
May 22, 2024 | marketbeat.com
Editas Medicine (NASDAQ:EDIT) Stock Price Up 11.6%
Editas Medicine (NASDAQ:EDIT) Stock Price Up 11.6%
May 16, 2024 | marketbeat.com
Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Recommendation of "Moderate Buy" by Brokerages
Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) has been given a consensus rating of "Moderate Buy" by the ten analysts that are presently covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold rating and five have assigned a buy rating to the
May 15, 2024 | seekingalpha.com
Editas Medicine: Promising Milestone Achieved But Be Patient
May 15, 2024 | marketbeat.com
Editas Medicine (NASDAQ:EDIT) Shares Gap Up on Insider Buying Activity
Editas Medicine (NASDAQ:EDIT) Shares Gap Up on Insider Buying Activity
May 15, 2024 | insidertrades.com
Editas Medicine, Inc. (NASDAQ:EDIT) Director Jessica Hopfield Acquires 45,000 Shares
May 14, 2024 | finance.yahoo.com
Director Jessica Hopfield Acquires 45,000 Shares of Editas Medicine Inc (EDIT)
May 14, 2024 | marketbeat.com
Insider Buying: Editas Medicine, Inc. (NASDAQ:EDIT) Director Buys 45,000 Shares of Stock
Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) Director Jessica Hopfield acquired 45,000 shares of the stock in a transaction on Monday, May 13th. The stock was bought at an average price of $5.64 per share, with a total value of $253,800.00. Following the transaction, the director now directly owns 67,700 shares of the company's stock, valued at approximately $381,828. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
May 14, 2024 | globenewswire.com
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
May 12, 2024 | finance.yahoo.com
Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
May 10, 2024 | markets.businessinsider.com
Buy Rating Affirmed for Editas Medicine Amid Promising CRISPR Pipeline and Growth Potential
May 10, 2024 | markets.businessinsider.com
Editas Medicine Hold Rating: Balancing Pipeline Potential with Financial and Legal Prudence
May 10, 2024 | globenewswire.com
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
May 9, 2024 | marketbeat.com
Editas Medicine (NASDAQ:EDIT) Price Target Cut to $15.00
Citigroup reduced their price objective on Editas Medicine from $16.00 to $15.00 and set a "buy" rating for the company in a research report on Thursday.
May 9, 2024 | finance.yahoo.com
Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript
May 9, 2024 | marketbeat.com
Editas Medicine (NASDAQ:EDIT) Releases Quarterly Earnings Results, Misses Expectations By $0.13 EPS
Editas Medicine (NASDAQ:EDIT - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.13). The firm had revenue of $1.10 million during the quarter, compared to the consensus estimate of $11.14 million. Editas Medicine had a negative return on equity of 42.95% and a negative net margin of 196.12%. The firm's revenue for the quarter was down 88.9% compared to the same quarter last year. During the same period last year, the company earned ($0.71) EPS.
May 9, 2024 | fool.com
1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?
May 9, 2024 | markets.businessinsider.com
Editas Medicine’s Innovative In Vivo Gene Editing Approach and Positive Clinical Trial Prospects Bolster Buy Rating
May 9, 2024 | markets.businessinsider.com
Buy Rating for Editas Medicine: Promising Trials and Solid Financial Footing Propel Growth Outlook
May 9, 2024 | marketbeat.com
Editas Medicine (NASDAQ:EDIT) Lifted to Equal Weight at Morgan Stanley
Morgan Stanley raised Editas Medicine from an "underweight" rating to an "equal weight" rating and set a $7.00 price target for the company in a report on Thursday.
May 9, 2024 | finance.yahoo.com
Editas Medicine First Quarter 2024 Earnings: Misses Expectations
May 8, 2024 | washingtonpost.com
Editas: Q1 Earnings Snapshot
May 8, 2024 | investorplace.com
EDIT Stock Earnings: Editas Medicine Misses EPS, Misses Revenue for Q1 2024
May 8, 2024 | globenewswire.com
Editas Medicine Announces First Quarter 2024 Results and Business Updates
May 7, 2024 | msn.com
Gene Editing Improves Vision in Rare and Devastating Retinal Disorder
May 7, 2024 | msn.com
Editas Medicine Q1 2024 Earnings Preview
May 7, 2024 | markets.businessinsider.com
What Wall Street expects from Editas Medicine's earnings
May 6, 2024 | msn.com
CRISPR gene editing shows promise for treating individuals with a form of inherited blindness
May 6, 2024 | msn.com
Clinical trial shows measurable improvement in inherited blindness after gene therapy
May 5, 2024 | finance.yahoo.com
Editas Medicine, Inc. (NASDAQ:EDIT) is a favorite amongst institutional investors who own 71%
May 3, 2024 | marketbeat.com
Editas Medicine (EDIT) to Release Earnings on Wednesday
Editas Medicine (NASDAQ:EDIT) will be releasing earnings before the market opens on Wednesday, May 8, Zacks reports.
May 2, 2024 | globenewswire.com
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
May 2, 2024 | uk.finance.yahoo.com
Stocks search for direction ahead of Fed rate decision
May 1, 2024 | msn.com
Editas, Bristol Myers extend T cell therapy collaboration
May 1, 2024 | globenewswire.com
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
April 29, 2024 | marketbeat.com
Editas Medicine, Inc. (NASDAQ:EDIT) Sees Large Increase in Short Interest
Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 18,760,000 shares, a growth of 14.7% from the March 31st total of 16,360,000 shares. Based on an average trading volume of 1,910,000 shares, the short-interest ratio is presently 9.8 days.
April 26, 2024 | marketbeat.com
Zacks Research Analysts Boost Earnings Estimates for Editas Medicine, Inc. (NASDAQ:EDIT)
Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Investment analysts at Zacks Research increased their Q3 2025 EPS estimates for shares of Editas Medicine in a research note issued on Wednesday, April 24th. Zacks Research analyst A. Chakraborty now anticipates that the company will post earnin
Get Editas Medicine News Delivered to You Automatically

Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter.

Biden to Launch “FedNOW” [Move Your Money Now] (Ad)

Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...

Get your free information kit NOW, before it's too late.

EDIT Media Mentions By Week

EDIT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

EDIT
News Sentiment
▼
0.82

0.76
▲
Average
Medical
News Sentiment

EDIT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

EDIT Articles
This Week
▼
9

3
▲
EDIT Articles
Average Week

Get Editas Medicine News Delivered to You Automatically

Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:EDIT) was last updated on 6/10/2024 by MarketBeat.com Staff

From Our Partners
AI's Next Magnificent Seven
The Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.
The Oxford Club | Sponsored
It's time to ween off Chinese lithium!
As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...
Smallcaps Daily | Sponsored
Top 5 Tech Stocks to Buy for 2024
The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...
Daily Market Alerts | Sponsored
Top 5 AI Stocks to Buy for 2024
The electric vehicle boom is accelerating – and fast.
Market Moving Trends | Sponsored
No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free
Optimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...
Hedgeye | Sponsored
Moonshot Coins for the Current Crypto Run
Did you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...
Crypto 101 Media | Sponsored
The Only Energy Play You Should Be Looking At
Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...
Wealthpin Pro | Sponsored
The Most Dangerous Time for 401k Owners
The world's most powerful CEO just issued a grave warning to Americans... "This may be the most dangerous t...
Birch Gold | Sponsored